Ventana Biotech Inc ("Ventana") (VNTA.PK), a biotechnology company that is developing a ground breaking appetite-suppressing chewing gum, today announced it is starting the next round of fund raising.
Ventana is today announcing that it has retained legal counsel for the company for the purpose of engaging the company in the process of obtaining full registration with SEC with the view to file a 15-c211 application later in 2009 enabling the company to obtain a full reporting Over-The-Counter "OTC" status before Q3 2009.
The management team is delighted with this progress as it will enable the company to increase the transparency for all its current shareholders as well as future ones, it will further more prove to be beneficial when the company later in the year aims to start negotiating the acquisitions for further IP and patents rights.
About Ventana Biotech Inc
Ventana is positioning itself as the leading bioscience company in the development and commercial licensure of novel therapeutic anti-obesity drug treatment. The company leverages cutting-edge research collaborations to achieve breakthroughs in innovative anti-obesity treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.
www.ventanabiotech.com
For more information about Ventana Biotech Inc please contact investor@ventanabiotech.com | |
No comments:
Post a Comment